MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky Sells 6,939 Shares

MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky sold 6,939 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total value of $22,066.02. Following the completion of the sale, the chief financial officer now directly owns 111,811 shares in the company, valued at approximately $355,558.98. The trade was a 5.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

MaxCyte Stock Up 0.7 %

Shares of MaxCyte stock opened at $3.09 on Friday. MaxCyte, Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $5.26. The business’s fifty day moving average is $4.04 and its two-hundred day moving average is $3.93. The firm has a market cap of $327.63 million, a PE ratio of -9.09 and a beta of 1.35.

Hedge Funds Weigh In On MaxCyte

Several large investors have recently added to or reduced their stakes in the business. Royce & Associates LP grew its holdings in MaxCyte by 59.8% in the 3rd quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock valued at $1,260,000 after buying an additional 121,272 shares during the period. Intech Investment Management LLC purchased a new stake in MaxCyte in the third quarter valued at approximately $51,000. Mudita Advisors LLP grew its holdings in MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after purchasing an additional 167,101 shares during the period. Verition Fund Management LLC raised its stake in MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares during the period. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in shares of MaxCyte by 13.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after purchasing an additional 169,250 shares during the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MXCT. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a “buy” rating in a research report on Wednesday, March 12th. Stifel Nicolaus reduced their target price on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.